Jane H.

Jane H. has an extensive work experience in the medical field, beginning with their role as Group Medical Director at Genentech in 2005. Jane then moved on to become Vice President, Head of Clinical Development at Acerta in 2015, followed by Chief Medical Officer, Hematology at BeiGene in 2016. In 2021, they became an Independent Board Director at Protara Therapeutics, and in 2022 they took on the roles of President and Chief Medical Officer at Prelude Therapeutics, as well as Independent Board Director at 858 Therapeutics.

Jane H. has attended Stanford University and the University of Washington.